StreetInsider.com News Articles

Form 424B5 Axogen, Inc.

Thu, 10 Sep 2026 16:57:00 -0400

si-local-file:///var/storage/secattach/20260910/27049216.html

Form 8-K/A Axogen, Inc. For: Sep 09

Thu, 10 Sep 2026 16:55:00 -0400

si-local-file:///var/storage/secattach/20260910/27049207.html

Form 8-K Axogen, Inc. For: Sep 09

Thu, 10 Sep 2026 06:03:00 -0400

si-local-file:///var/storage/secattach/20260910/27044660.html

Axogen prices $208.7M stock offering to fund BioCircuit acquisition

Thu, 10 Sep 2026 06:01:11 -0400

Axogen, Inc. (NASDAQ: AXGN) has priced an underwritten public offering of 4,910,000 shares of common stock at $42.50 per share, according to a company statement. The gross proceeds are expected to total approximately $208.7 million, before underwriting discounts, commissions, and other expenses.

The company has also granted underwriters a 30-day option to purchase up to an additional 736,500 shares at the public offering price. The offering is expected to close on Sept. 11, 2026, subject to customary closing conditions.

Axogen said it intends to use substantially all of the net proceeds to fund the cash consideration for its previously announced acquisition of

Axogen Announces Pricing of $208.7 Million Public Offering of Common Stock

Thu, 10 Sep 2026 06:01:00 -0400

ALACHUA, Fla. and TAMPA, Fla., Sept. 10, 2026 (GLOBE NEWSWIRE) -- Axogen, Inc. (“Axogen” or the “Company”) (Nasdaq: AXGN), a global leader in developing and marketing innovative surgical solutions for the restoration of peripheral nerve function, today announced the pricing of an underwritten public offering of 4,910,000 shares of its common stock at a price to the public of $42.50 per share, before underwriting discounts and commissions. All of the shares to be sold in the proposed offering are to be sold by Axogen. In addition, Axogen has granted the underwriters a 30-day option to purchase up

Axogen Announces Pricing of $208.7 Million Public Offering of Common Stock

Thu, 10 Sep 2026 06:01:00 -0400

Axogen to acquire BioCircuit Technologies for $200M in cash

Thu, 10 Sep 2026 06:00:30 -0400

Axogen, Inc. (NASDAQ: AXGN) has entered into a definitive agreement to acquire BioCircuit Technologies, Inc., a privately held medical device company, for $200 million in cash, according to a press release from Axogen.

BioCircuit, based in Atlanta, Georgia, is the developer of NerveTape, which the company claims is the first FDA-approved device for sutureless peripheral nerve repair. The product allows surgeons to align, connect, and protect transected nerves without microsutures.

Under the terms of the agreement, $1.0 million of the estimated merger consideration will be withheld pending determination of a post-closing purchase price adjustment. The transaction is expected to close in the

Axogen Enters into Definitive Agreement to Acquire BioCircuit Technologies

Thu, 10 Sep 2026 06:00:00 -0400

Acquisition adds NerveTape™, the 1st FDA-approved device for sutureless peripheral nerve repair, broadening Axogen’s addressable market within its focus markets

Axogen’s commercial infrastructure, surgeon relationships and hospital contracting are expected to accelerate adoption and expand access to NerveTape™

Transaction expected to be accretive to revenue growth, adjusted EBITDA margin and adjusted EPS in the first year following closing while Axogen remains free cash flow positive

ALACHUA, Fla. and TAMPA, Fla., Sept. 10, 2026 (GLOBE NEWSWIRE) -- Axogen, Inc. (“Axogen” or the “Company”) (Nasdaq: AXGN), a global leader in

Axogen Enters into Definitive Agreement to Acquire BioCircuit Technologies

Thu, 10 Sep 2026 06:00:00 -0400

Acquisition adds NerveTape™, the 1st FDA-approved device for sutureless peripheral nerve repair, broadening Axogen’s addressable market within its focus markets

Axogen’s commercial infrastructure, surgeon relationships and hospital contracting are expected to accelerate adoption and expand access to NerveTape™

Transaction expected to be accretive to revenue growth, adjusted EBITDA margin and adjusted EPS in the first year following closing while Axogen remains free cash flow positive

ALACHUA, Fla. and TAMPA, Fla., Sept. 10, 2026 (GLOBE NEWSWIRE) -- Axogen, Inc. (“Axogen” or the “Company”) (Nasdaq: AXGN), a global leader in

Axogen, Inc. to Participate in the 24th Annual Morgan Stanley Global Healthcare Conference

Tue, 01 Sep 2026 07:00:00 -0400

ALACHUA, Fla. and TAMPA, Fla., Sept. 01, 2026 (GLOBE NEWSWIRE) -- Axogen, Inc. (NASDAQ: AXGN), a global leader in developing and marketing innovative surgical solutions for the restoration of peripheral nerve function, today announced that management will be available for one-on-one investor meetings at the 24^th Annual Morgan Stanley Global Healthcare Conference on Tuesday, September 15, 2026.

About Axogen

Axogen (AXGN) is the leading company focused specifically on the science, development and commercialization of technologies for peripheral nerve regeneration and repair. Axogen employees are passionate about providing the opportunity to restore nerve function and quality of

Axogen, Inc. to Participate in the 24th Annual Morgan Stanley Global Healthcare Conference

Tue, 01 Sep 2026 07:00:00 -0400

About Axogen

Truist Securities Starts AxoGen, Inc. (AXGN) at Buy

Wed, 26 Aug 2026 05:02:25 -0400

Truist Securities analyst Ravi Misra initiates coverage on AxoGen, Inc. (NASDAQ: AXGN) with a Buy rating and a price target of $60.00.

The analyst comments "Initiating with Buy and $60 PT on AXGN, a unique high-growth peripheral nerve repair co, mkting the first (and only) Biologic allograft (Avance) w/in a portfolio of nerve repair products. AXGN plays in a large, barely penetrated TAM (~$5B) and should be capable of supporting dd growth across a wide set of procedures. Even with substantial outperformance (238% LTM vs. -10% IHI) we see room to run further and durable upside to our above CNS 20%+

Truist Securities Starts AxoGen, Inc. (AXGN) at Buy

Wed, 26 Aug 2026 05:02:25 -0400

Truist Securities analyst Ravi Misra initiates coverage on AxoGen, Inc. (NASDAQ: AXGN) with a Buy rating and a price target of $60.00.

Form SCHEDULE 13G/A Axogen, Inc. Filed by: First Light Asset Management, LLC

Fri, 14 Aug 2026 16:41:00 -0400

si-local-file:///var/storage/secattach/20260814/26931892.html

Form SCHEDULE 13G/A Axogen, Inc. Filed by: First Light Asset Management, LLC

Fri, 14 Aug 2026 16:41:00 -0400

si-local-file:///var/storage/secattach/20260814/26931892.html

Form 4 Axogen, Inc. For: Aug 10 Filed by: Began Marc A

Wed, 12 Aug 2026 16:14:00 -0400

si-local-file:///var/storage/secattach/20260812/26912996.html

Form 4 Axogen, Inc. For: Aug 10 Filed by: Began Marc A

Wed, 12 Aug 2026 16:14:00 -0400

si-local-file:///var/storage/secattach/20260812/26912996.html

Form 4 Axogen, Inc. For: Aug 11 Filed by: Wendell Amy McBride

Wed, 12 Aug 2026 16:13:00 -0400

si-local-file:///var/storage/secattach/20260812/26912985.html

Form 4 Axogen, Inc. For: Aug 11 Filed by: Wendell Amy McBride

Wed, 12 Aug 2026 16:13:00 -0400

si-local-file:///var/storage/secattach/20260812/26912985.html

Form 144 Axogen, Inc. Filed by: Wendell Amy McBride

Tue, 11 Aug 2026 16:30:00 -0400

si-local-file:///var/storage/secattach/20260811/26906300.html

Form 144 Axogen, Inc. Filed by: Wendell Amy McBride

Tue, 11 Aug 2026 16:30:00 -0400

si-local-file:///var/storage/secattach/20260811/26906300.html

Form 4 Axogen, Inc. For: Aug 07 Filed by: Weiler Kathy Johnson

Tue, 11 Aug 2026 16:16:00 -0400

si-local-file:///var/storage/secattach/20260811/26905948.html

Form 4 Axogen, Inc. For: Aug 07 Filed by: Weiler Kathy Johnson

Tue, 11 Aug 2026 16:16:00 -0400

si-local-file:///var/storage/secattach/20260811/26905948.html

Cosmetic Surgery's Next Debate: Rebuild Tissue, Not Fill It

Tue, 11 Aug 2026 15:35:51 -0400

News Provided by Biotech Insider on behalf of Conexeu Sciences Inc.

RENO, Nev., Aug. 11, 2026 (GLOBE NEWSWIRE) -- Biotech Insider News Commentary - For thirty years the answer to lost facial and body volume has been to put something back in. Fillers occupy space, implants occupy space, and the industry built around them optimized for predictability and reversibility rather than for biology. That framework is now under real pressure, partly because GLP-1's success in weight loss has expanded the population needing volume restoration at a scale the injectable toolkit was never designed for, and

Cosmetic Surgery's Next Debate: Rebuild Tissue, Not Fill It

Tue, 11 Aug 2026 15:35:51 -0400

News Provided by Biotech Insider on behalf of Conexeu Sciences Inc.